NCT06167694View on ClinicalTrials.gov

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Unresectable or Metastatic Breast Cancer
Interventions
DRUG

HRS-8080; Dalpiciclib Isethionate Tablets

HRS-8080 combined with Dalpiciclib Isethionate Tablets

Trial Locations (1)

100000

RECRUITING

Chinese PLA General Hospital Fifth Medical Center, Beijing

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY